US election results good for global equities

Joe Biden was declared the winner of the US presidential race, and is likely to take office with a Republican Senate. The stage is set for sustained US dollar weakness and the continued outperformance of emerging market assets.

09 Nov 2020

Key highlights: What does Joe Biden’s win mean for fiscal support and markets?

  • Recent comments from legislators suggest this outcome likely leads to at least some additional fiscal support, reducing the tail risks associated with divided government.
  • The stage is set for sustained US dollar weakness and the continued outperformance of emerging market assets.
  • The odds of legal challenges reversing the outcome of the presidential vote are negligible.

US election results Market reaction and implications

We believe that the early cycle environment remains positive for global equities and the tactical outperformance of cyclical segments of the market.

In our view, the clearest market implication of the election is that the stage is set for sustained softness in the US dollar and the outperformance of emerging market assets.

Most of the protectionism discount embedded in foreign assets is slated to fade, and a moderation in the outlook for fiscal stimulus likely reduces the odds of a disorderly spike in real yields that could buoy the greenback.

Emerging market (EM) currencies trade at attractive valuations and have among the most catch-up potential of the procyclical trade set. We believe that EM equities are poised to benefit from this currency appreciation, while positive trends in global trade as well as Chinese manufacturing imports and credit growth support continued outperformance. The growth outlook could receive another tailwind before year-end, by which time we expect the emergency approval of at least one COVID-19 vaccine by the US Food and Drug Administration.

Financial assets have reacted positively to the conclusion of the elections. Implied volatility across asset classes had been rising ahead of the event, and proceeded to tumble after Election Day. In our view, investors have correctly extrapolated that the result is clear, and any attempts to contest the election will not be worthy of serious consideration or alter the current outcome across several states.

Volatility craters after the US vote

Z-score of where implied volatility for different assets stands relative to its one-year average

Source: UBS Asset Management, Bloomberg. As of 6 November 2020.

US election results Transition turmoil?

Based on the election results, there is still more than 5% of the Trump presidency left before the Jan. 20 inauguration. This transition period includes both the prospect of a contested election and geopolitical risks that may contribute to market volatility.

We ascribe negligible, near-zero odds to a potential reversal of the declared outcome of the presidential election. Biden has secured a plurality of votes in more than enough states to command an electoral college majority. And in swing states, particularly Pennsylvania, his margin of victory is sufficient based on votes cast by the day of the election.
Legal challenges to the voting protocols as well as the election results in many states are already underway, and the possibility of recounts looms. The president pledged that there would be lots of litigation, which we expect will be manifold, broad in scope, and have varying degrees of credibility and materiality. An important factor to monitor will be the final reported margin of victory in a collection of states that give Biden at least 270 electoral college votes. The bigger this is, the lower the likelihood that legal challenge(s) would result in a different outcome. In any event, the experience of 2000 suggests that all legal challenges should be resolved by Dec. 8, the safe harbor deadline by which states must certify their election results.

A primary focus on domestic considerations pertaining to the presidential election result over the transition period may diminish the risk of international disputes. But we do see a meaningful threat of an escalation in US-China tensions initiated by an outgoing president who may blame China as the cause of negative socioeconomic conditions that prevailed in 2020. Measures could include an end to phase one trade deal, bans on the use of Chinese e-commerce payment platforms by US corporates, and sanctions against Chinese/Hong Kong banks.

We expect China would continue to hold off on strong retribution to any fresh measures imposed by the Trump administration, judging that they would be undone early in Biden’s tenure. We suspect markets too would be able to “look through” some of these developments. That said, we also see a non-negligible risk of an escalation of tensions in the South China Sea or elsewhere in the region during this transition phase in US leadership.

Actions taken in the transition period are not likely to cause irreversible damage, but the US-China relationship already appears to be on an irreversibly negative trajectory. We do not believe that this will change under a Biden administration.

US election results US-China under Biden

In our view, Biden’s approach towards China is poised to be more predictable, but still confrontational. There will be less emphasis on the balance of trade and a gradual move away from tariffs, but technology will serve as a focal point in the continuing deterioration of US-China relations. Unlike the outgoing president, Biden may choose to build multilateral coalitions with American allies to address China on matters pertaining to trade, technology, human rights, and the environment.

The incoming president’s methods for leveling perceived inequities in the US-China relationship will likely focus on building up the US, to the extent Congress is amenable, rather than measures in which the primary aim is to curtail Chinese production.

US election results Conclusion:

The passing of the US elections allows investors to begin to focus less on policy risks and more on the global economic recovery from the COVID-19 downturn. Now that the relief rally has seen investors price out some of the negatives that may have accompanied a Blue Wave or highly disputed, inconclusive election, underlying trends that were in place before the election are poised to resume. We are cognizant of near-term downside risks pertaining to COVID-19, chiefly a more severe than anticipated seasonal wave of infections and ensuing mobility restrictions as well as the potential for delays and disappointment on vaccine development. Such a backdrop could elicit a return to the outperformance of tech stocks, particularly ones that benefit from a stay-at-home environment. Our procyclical bias would be challenged in this situation. Ultimately, we expect the market to be forward-looking and focus primarily on re-opening in 2021, even if the growth outlook faces intermittent headwinds.

We have the highest conviction in sustained dollar weakness and the outperformance of emerging market assets. A diminished threat of tariffs under the incoming administration should reduce much of the protectionism discount in foreign currencies and reverse prior US dollar strength. The lack of an aggressive fiscal impulse stateside will keep real yields subdued, in our view, also contributing to a broad downdraft in the dollar. We deem a broad swath of emerging market assets – from foreign exchange, to equities, to dollar-denominated debt – to be particularly attractive in this backdrop.

Nasdaq 100 earnings, price outperformance fading in early-cycle environment as policy risks mount

Source: UBS Asset Management. Chart as of 30 October 2020.

The forward earnings outlook points to stronger profit growth for the broader US market relative to tech-heavy Nasdaq 100 Index in the coming year, which informs our bias towards value, procyclical stocks.

US small caps, which have the most leverage to the improving domestic economy, should also outperform their larger cap peers.

The ongoing normalization of the global economy and expected development of a trusted, effective vaccine are shaping up to be the dominant features of the macroeconomic and market backdrop in the months to come. While the lack of a clear Blue Wave failed to spark a swift procyclical rotation, we believe that the presence and proximity of these catalysts bodes well for the sustained success of this trade set over time as the expansion progresses.

More insights

Subscribe now

Perspectives matter. Tune in to our insights.

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.